NanoViricides Inc. (NNVC)

[drkazmd65]

If that nonsense were true, why did NNVC quit working on Ebolacide for years then suddenly, as is the case with other diseases-of-the-month, now NNVC is back at it?

A simple set of questions to answer if one had already been paying attention.

1) The company 'quit' working on the Ebolacide formulations because the funding that they had recieved (a CRADA) was not renewed after 2009. Combined with the fact that the research source of money had dried up for doing follow-up work, there was no market for an Ebolacide drug to justify the company putting its own limited financial resources into further development at the time.

So - instead - the decision was made to focus on Flucide - where testing is easier to accomplish as potential patients are large in number, where there is a regular influx of new patients who might need treatment for Flu, and where money was to be made.


2) The decision was made to restart the work because of a few related factors.
a) The Ebola outbreak and committment from organizations like WHO for research money could reopen a path for financing to do the remaining work that needs to be done.
b) The added information that the previous gene target that Ebolacide I was aimed at was probably not the ideal target was discovered in the meantime. Instead - a different target is mimiced in Ebolacide II that appears to be the correct one.
c) With the R&D for Flucide development in the can - and only the scale-up work remaining (given substantial) - there is/was time for Ebolacide II R&D.
d) The company's fairly substantial cash standing gives it some breathing room to do a bit of preliminary work on its own even before getting money from WHO or a Government source to do scale up.

But - those paying attention already know this.